Kyushu University Academic Staff Educational and Research Activities Database
Researcher information (To researchers) Need Help? How to update
Masahiro Mizoguchi Last modified date:2019.07.02

Associate Professor / Department of Neurosurgery, Graduate School of Medical Sciences, Kyushu University
Neurological Institute
Faculty of Medical Sciences

Graduate School
Undergraduate School
Other Organization

Department of Neurosurgery, Graduate School of Medical Sciences, Kyushu University .
Academic Degree
Medical science
Field of Specialization
Outline Activities
Molecular genetic analysis of brain tumors
Research Interests
  • Molecular genetic analysis of brain tumors
    keyword : brain tumor, genetics, signaling pathway, molecular target therapy
  • MicroRNA regulation for "stemness" in brain tumor stem cell
    keyword : Brain tumor stem cell (BTSC) microRNA
    2010.06~2013.03Implication of microRNA in brain tumor stem cells.
  • Expression of miroRNA and alteration of signaling pathways in brain tumor stem cells
    keyword : Brain tumor stem cell (BTSC) microRNA
    2005.06~2009.03Implication of microRNA in brain tumor stem cells.
Academic Activities
1. Masahiro Mizoguchi, Koji Yoshimoto, Tomio Sasaki, Patient Surveillance After Cancer Treatment
Glioma of the Central Nervous System Surveillance Counterpoint: Japan
, Humana Press, 2013.02.
1. Masahiro Mizoguchi, Yanlei Guan, Koji Yoshimoto, Nobuhiro Hata, TOSHIYUKI AMANO, Akira Nakamizo, Tomio Sasaki, Clinical implications of microRNAs in human glioblastoma, Frontiers in Oncology, 2013.02.
2. Koji Yoshimoto, Masahiro Mizoguchi, Nobuhiro Hata, Hideki Murata, Ryusuke Hatae, TOSHIYUKI AMANO, Akira Nakamizo, Tomio Sasaki, Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma, 2012.12.
3. Masahiro Mizoguchi, Yanlei Guan, Koji Yoshimoto, Nobuhiro Hata, TOSHIYUKI AMANO, Akira Nakamizo, Tomio Sasaki, MicroRNAs in Human Malignant Gliomas, 2012.10.
4. Koji Yoshimoto, Masahiro Mizoguchi, Nobuhiro Hata, TOSHIYUKI AMANO, Akira Nakamizo, Tomio Sasaki, Molecular biomarkers of glioblastoma: current targets and clinical implications, 2012.10.
5. Mizoguchi M, Kuga D, Guan Y, Hata N, Nakamizo A, Yoshimoto K, Sasaki T., Loss of heterozygosity analysis in malignant gliomas., Brain Tumor Pathol, 2011.07, Despite recent advances in the diagnosis and treatment of glioblastomas, patient outcomes for these highly malignant tumors remain poor. Research into the molecular pathology of glioblastoma has uncovered various genetic changes that contribute to malignancy. Some of the identified molecular markers--such as loss of heterozygosity (LOH) on chromosome 1p/19q and chromosome 10, O6-methylguanine methyltransferase promoter hypermethylation, and mutation of isocitrate dehydrogenase-1--may help to predict patient outcomes. Indeed, LOH analysis is an effective approach to classify malignant gliomas. Genome-wide analyses have revealed that the extent and pattern of LOH regions may have important implications for the clinical course of the disease. As the genetic underpinnings of malignant gliomas are complex and varied, careful selection of the methods for genetic analysis in the clinic is important. The fundamental principles of each assay need to be understood to allow careful selection of practically useful methods. This review summarizes recent developments in the molecular analysis of malignant glioma..
1. Akira Nakamizo, TOSHIYUKI AMANO, Masahiro Mizoguchi, Koji Yoshimoto, Tomio Sasaki, Dorsal location of the cochlear nerve on vestibular schwannoma: preoperative evaluation, frequency, and functional outcome., Neurosurg Rev, 36, 1, 39-43, 2013.01.
2. Yamashita Koji, Takashi Yoshiura, Hiwatashi Akio, Osamu Togao, Koji Yoshimoto, Satoshi O Suzuki, Masahiro Mizoguchi, Toru Iwaki, Hiroshi Honda, Differentiating primary CNS lymphoma from glioblastoma multiforme: assessment using arterial spin labeling, diffusion-weighted imaging, and (18)F-fluorodeoxyglucose positron emission tomography, 10.1007/s00234-012-1089-6., 55, 2, 135-143, 2013.02.
3. Xinlong Ma, Koji Yoshimoto, Yanlei Guan, Nobuhiro Hata, Masahiro Mizoguchi, Noriaki Sagata, Hideki Murata, Daisuke Kuga, TOSHIYUKI AMANO, Akira Nakamizo, Tomio Sasaki, Associations between microRNA expression and mesenchymal marker gene expression in glioblastoma, 10.1093/neuonc/nos145, 14, 9, 1153-1162, 2012.09.
4. Masahiro Mizoguchi, Koji Yoshimoto, Xilong Ma, Yanlei Guan, Nobuhiro Hata, TOSHIYUKI AMANO, Akira Nakamizo, Satoshi O Suzuki, Toru Iwaki, Tomio Sasaki, Molecular characteristics of glioblastoma with 1p/19q co-deletion, 10.1007/s10014-012-0107-z, 29, 3, 148-153, 2012.07.
5. Sasaki T, Hashiguchi K, Yoshimoto K, Nakamizo A, Mizoguchi M; Neurosurgical Staff of Kyushu University, Worldwide academic contributions of Japanese neurosurgeons, Neurol Med Chir (Tokyo), 51, 6, 405-414, 2011.06, Based on the data reported in the National Institute of Science and Technology Policy 2010, Japan is ranked in fourth place in the world in terms of the numbers of the articles in the fields of clinical medicine. However, there had not been any objective data regarding the numbers of publications by neurosurgeons. As it is important for neurosurgeons to realize the extent of academic contributions by the neurosurgeons in different countries, the numbers of publications in the major journals by the members of the Japan Neurosurgical Society and those from neurosurgical institutions around the world were analyzed using both the biomedical literature database PubMed and the publication database "ISI Web of Knowledge." Parts of the results were presented in the 69th Annual Meeting of the Japan Neurosurgical Society. As to the number of neurosurgical publications in English from the top 9 countries, the US has been consistently in first place and Japan in second. However, the number of publications from Japan has been decreasing since 2000. With regards to the "top 8 journals" such as the Lancet and the Journal of the American Medical Association, the number of first-author publications by Japanese neurosurgeons increased in the late 1980s and had been 2-9 articles per year until recently. In the "top 12 neuroscience journals" which include Stroke, Neuro-Oncology, Cancer Research, and others, Japan had been in the third next to the US and UK till 2004, but Germany surpassed Japan in 2005. In the "top 6 clinical journals" such as the Journal of Neurosurgery and Neurosurgery, the US has been consistently keeping first place and Japan second place since 1977. Searches using the key word elucidated that Japanese neurosurgeons are greatly contributing in the field of "aneurysm." Regarding the number of publications per neurosurgeon, Canada and UK are in the forefront and Japan is down to eighth place. Japanese neurosurgeons have been contributing greatly next to the Americans to the field of clinical neurosurgery and neuroscience by publishing in English. However, the number of publications by Japanese neurosurgeons has been declining since 2000. The Japan Neurosurgical Society must come up with countermeasures to address this problem..
6. Yoshimoto K, Ma X, Guan Y, Mizoguchi M, Nakamizo A, Amano T, Hata N, Kuga D, Sasaki T, Expression of stem cell marker and receptor kinase genes in glioblastoma tissue quantified by real-time RT-PCR, Brain Tumor Pathol, 28, 4, 291-296, 2011.10, Glioblastoma is dependent on a specific signaling pathway to maintain its tumor phenotype. The receptor tyrosine kinase (RTK) family mediates the multiple oncogenic growth factor receptor signaling and contributes to the pathogenesis of glioblastoma. Recently, many studies have shown that the expression of stem cell marker in glioblastoma tissue has prognostic significance, which indicates that the quantification of stem cell markers and RTK genes yields biological information about glioblastoma. In this study, we quantified RNA expression levels of stem cell markers [CD133, Nestin, BMI-1, maternal embryonic leucine zipper kinase (MELK), and Notch1-4] as well as RTKs (EGFR, ErbB4, VEGFR1-3, FGFR1, -2, PDGFRΑ, and PDGFRΒ) in 42 clinical samples of glioblastoma by the real-time RT-PCR method. We demonstrated that the expression of MELK is exclusively upregulated in glioblastoma tissue. Notch receptor expression is moderately upregulated and is correlated with that of VEGFR2, VEGFR3, and PDGFRβ. Unsupervised clustering identified one unique sample group that showed high expression of most of the genes analyzed. Our results suggest that quantification of these stem cell markers and RTK genes can stratify patients based on the expression profile, which might provide insight into the glioma biology in each cluster..
7. Araki Y, Mizoguchi M, Yoshimoto K, Shono T, Amano T, Nakamizo A, Suzuki SO, Iwaki T, Sasaki T, Quantitative digital assessment of MGMT immunohistochemical expression in glioblastoma tissue, Brain Tumor Pathol, 28, 1, 25-31, 2011.02.
8. Guan Y, Mizoguchi M, Yoshimoto K, Hata N, Shono T, Suzuki SO, Araki Y, Kuga D, Nakamizo A, Amano T, Ma X, Hayashi K, Sasaki T., MiRNA-196 is upregulated in glioblastoma but not in anaplastic astrocytoma and has prognostic significance, Clin Cancer Res, 16, 16, 4289-97, 2010.08.
9. Kuga D, Mizoguchi M, Guan Y, Hata N, Yoshimoto K, Shono T, Suzuki SO, Kukita Y, Tahira T, Nagata S, Sasaki T, Hayashi K. , Prevalence of copy-number neutral LOH in glioblastomas revealed by genomewide analysis of laser-microdissected tissues. , Neuro Oncol, 10(6):995-1003, 2008.12.
10. Guan Y, Hata N, Kuga D, Yoshimoto K, Mizoguchi M, Shono T, Suzuki SO, Tahira T, Kukita Y, Higasa K, Yokoyama N, Nagata S, Iwaki T, Sasaki T, Hayashi K, Narrowing of the regions of allelic losses of chromosome 1p36 in meningioma tissues by an improved SSCP analysis, Int J Cancer, 122(8):1820-1826, 2008.04.
11. Mizoguchi M, Betensky RA, Batchelor TT, Bernay DC, Louis DN, Nutt CL , Activation of STAT3, MAPK, and AKT in Malignant Astrocytic Glioma: Correlation With EGFR status, Tumor Grade, and Survival, J Neuropath Exp Neurol, 65(12): 1181-1188, 2006.12.
1. Koji Yoshimoto, Masahiro Mizoguchi, Nobuhiro Hata, Tomio Sasaki, Diagnostic significance of microRNA and gene expression in glioma patients, The 4th International Symposium of Brain Tumor Pathology, 2012.05.
2. Masahiro Mizoguchi, Koji Yoshimoto, Nobuhiro Hata, TOSHIYUKI AMANO, Akira Nakamizo, Tomio Sasaki, Clinical Implications of Loss of Heterozygosity and IDH Mutation in Malignant Glioma, The 4th International Symposium of Brain Tumor Pathology, 2012.05.
3. Assessment of 1p/19q deletion in malignant gliomas.
4. Treatment strategy of malignant gliomas based on molecular analysis.
5. Loss of heterozygosity analysis of malignant gliomas using the PCR with multiple microsatellite markers.
6. Molecular pathology of malignant glioma.
7. Clinical implication of molecular pathology in malignant glioma.
8. Analysis of IDH1 mutation and LOH status in human glioma.
9. Molecular pathology of malignant glioma.
Membership in Academic Society
  • The Japan Neurosurgical Society
  • The Japanese Congress of Neurological Surgery
  • The Japan Society for Neuro-Oncology
  • The Japan Society of Brain Tumor Pathology
  • The Japanese Congress for Brain Tumor Surgery
  • The Japan Stroke Society
  • Japanese Society on Surgery for Cerebral Stroke
  • Japan Society for CNS Computed Imaging
  • The Japan Society of Molecular Neurosurgery
Educational Activities
Brain tumor: basic science (molecular patholoby, molecular biology), and clinical sturdy (surgical treatment, chemotherapy)